Novel treatment strategies in chronic lymphocytic leukemia Journal Article
| Author: | Weiss, M. A. |
| Article Title: | Novel treatment strategies in chronic lymphocytic leukemia |
| Abstract: | The recent introduction of new active agents has led to a renaissance of clinical investigation in chronic lymphocytic leukemia (CLL). These agents include three purine analogues, (pentostatin, fludarabine, and cladribine) and two monoclonal antibodies (rituximab and CAMPATH I-H). Careful clinical studies have allowed for the development of novel combinations of two and even three non-cross- resistant agents. These preliminary studies indicate that such combinations can induce complete responses in a larger proportion of patients than can single-agent therapy. In CLL, survival is superior for patients achieving a complete response compared with patients achieving a partial response. Therefore, strategies designed to induce high-quality responses in the majority of patients may one day lead to improved survival or possibly even cure in patients with chronic lymphocytic leukemia. |
| Keywords: | fludarabine; clinical trial; review; antineoplastic agents; antineoplastic agent; controlled clinical trial; randomized controlled trial; antineoplastic combined chemotherapy protocols; cyclophosphamide; monoclonal antibody; antibodies, monoclonal; randomized controlled trials; drug derivative; sex difference; sex factors; chronic lymphatic leukemia; chlorambucil; pentostatin; vidarabine; cladribine; leukemia, lymphocytic, chronic; humans; human; male; female |
| Journal Title: | Current Oncology Reports |
| Volume: | 3 |
| Issue: | 3 |
| ISSN: | 1523-3790 |
| Publisher: | Springer |
| Date Published: | 2001-06-01 |
| Start Page: | 217 |
| End Page: | 222 |
| Language: | English |
| PUBMED: | 11296131 |
| PROVIDER: | scopus |
| DOI: | 10.1007/s11912-001-0053-0 |
| DOI/URL: | |
| Notes: | Export Date: 21 May 2015 -- Source: Scopus |
